Clinical Trials
18 trialsNCT06686394 2026-05-22
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02693535 2026-05-15
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT05672524 2026-05-12
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05319873 2026-05-11
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT07413939 2026-05-11
BREnnA
Hoffmann-La Roche
Phase 2/3 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06157892 2026-05-05
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
NCT07494448 2026-04-23
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting
NCT05132582 2026-04-20
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT05458674 2026-04-03
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT03975647 2026-03-30
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT05748834 2026-03-20
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT05323955 2026-03-17
BRIDGET
Duke University
Phase 2 Active not recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT05382364 2026-03-12
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
Phase 1 Active not recruiting